Celcuity (CELC) Return on Capital Employed (2017 - 2026)
Celcuity's (CELC) quarterly Return on Capital Employed came in at 40.31% in Q4 2025, up 951.0% YoY from 3.84% in Q4 2024, and up 26.41% on a QoQ basis from 54.78% in Q3 2025.
Celcuity (CELC) Return on Capital Employed (2017 - 2026) Analysis & Trends
Celcuity (CELC) has 9 years of Return on Capital Employed data on file, last reported at 40.31% in Q4 2025.
- Quarterly Return on Capital Employed rose 951.0% year-over-year to 40.31% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 40.31% (up 951.0% YoY) and the FY2025 annual result came in at 55.24%, up 550.0% from the prior year.
- Return on Capital Employed advanced to 40.31% in Q4 2025, from 54.78% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 27.01% in Q1 2023 to a low of 91.12% in Q2 2025.
- A 5-year average of 45.4% and a median of 42.2% in 2021 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2021 — Return on Capital Employed soared 4212 bps — and 2025, when it sank 5245 bps.
- Tracing CELC's Return on Capital Employed over 5 years: stood at 32.83% in 2021, then slipped by 6 bps to 34.67% in 2022, then dropped by 25 bps to 43.4% in 2023, then slipped by 15 bps to 49.82% in 2024, then increased by 19 bps to 40.31% in 2025.
- The last three Return on Capital Employed figures came in at 40.31% (Q4 2025), 54.78% (Q3 2025), and 91.12% (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | -36.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -36.07% |
| Dec 31, 2025 | -40.31% |
| Sep 30, 2025 | -54.78% |
| Jun 30, 2025 | -91.12% |
| Mar 31, 2025 | -63.87% |
| Dec 31, 2024 | -49.82% |
| Sep 30, 2024 | -37.65% |
| Jun 30, 2024 | -38.67% |
| Mar 31, 2024 | -44.03% |
| Dec 31, 2023 | -43.40% |
| Sep 30, 2023 | -42.99% |
| Jun 30, 2023 | -32.79% |
| Mar 31, 2023 | -27.01% |
| Dec 31, 2022 | -34.67% |
| Sep 30, 2022 | -54.80% |
| Jun 30, 2022 | -40.32% |
| Mar 31, 2022 | -41.67% |
| Dec 31, 2021 | -32.83% |
| Sep 30, 2021 | -38.12% |
| Jun 30, 2021 | -56.41% |